CLDX vs TRIB
Celldex Therapeutics, Inc. and Trinity Biotech PLC, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CLDX | TRIB |
|---|---|---|
| Revenue | $1.5M | $61.6M |
| Net income | $-258.8M | $-31.8M |
| Gross margin | 87.1% | 34.8% |
| Net margin | · | −50.7% |
| Return on equity | −40.6% | · |
| Diluted EPS | −$3.90 | · |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-213.7M | $-4.6M |
| Equity | $527.2M | · |
| Net debt / equity | · | · |
| Current ratio | 10.49× | 1.28× |
| Revenue CAGR 5y | −26.9% | −7.4% |
| Profit CAGR 5y | · | · |
TRIB bills 39.8× the revenue of CLDX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | CLDX | TRIB |
|---|---|---|
| FY2024 | $7.0M | $61.6M |
| FY2023 | $6.9M | $56.8M |
| FY2022 | $2.4M | $62.5M |
| FY2021 | $4.7M | $81.1M |
| FY2020 | $7.4M | $102.0M |
| FY2019 | $3.6M | $90.4M |
| FY2018 | $9.5M | $97.0M |
| FY2017 | $12.7M | $99.1M |
| FY2016 | $6.8M | $99.6M |
| FY2015 | $5.5M | $100.2M |
Bottom line
| Fiscal year | CLDX | TRIB |
|---|---|---|
| FY2024 | $-157.9M | $-31.8M |
| FY2023 | $-141.4M | $-24.0M |
| FY2022 | $-112.3M | $-41.0M |
| FY2021 | $-70.5M | $875,000 |
| FY2020 | $-59.8M | $-6.4M |
| FY2019 | $-50.9M | $-28.9M |
| FY2018 | $-151.2M | $-22.1M |
| FY2017 | $-93.0M | $-40.3M |
| FY2016 | $-128.5M | $-100.6M |
| FY2015 | $-127.2M | $21.8M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | −$54,535,000 | TRIB |
| FY2023 | −$49,949,000 | TRIB |
| FY2022 | −$60,164,000 | TRIB |
| FY2021 | −$76,498,000 | TRIB |
| FY2020 | −$94,562,000 | TRIB |
| FY2019 | −$86,862,000 | TRIB |
| FY2018 | −$87,497,000 | TRIB |
| FY2017 | −$86,397,000 | TRIB |
| FY2016 | −$92,825,000 | TRIB |
| FY2015 | −$94,715,000 | TRIB |
TRIB has reported the higher revenue in every one of these 10 fiscal years. The gap has narrowed since the earliest year compared.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
TRIB's return on equity has been more volatile than CLDX's over the 5 comparable fiscal years — 41.4 percentage points of standard deviation against 16.1.
5 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between CLDX and TRIB over these 5 fiscal years — CLDX led in 3 and TRIB in 2.
5 of 17 comparable fiscal years — a year missing data on either side is not counted.